{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLASSIA+120+mg%2Fkg",
    "query": {
      "intervention": "GLASSIA 120 mg/kg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T15:30:19.929Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05485155",
      "title": "Zemaira Eosinophilic Esophagitis Pilot Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Alpha-proteinase inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-05-15",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05485155"
    },
    {
      "nct_id": "NCT04722887",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 15%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Liquid Alpha1-Proteinase Inhibitor (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-08-13",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722887"
    },
    {
      "nct_id": "NCT02722304",
      "title": "Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Alpha1-antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "ARALAST NP 60 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ARALAST NP 120 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLASSIA 60 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLASSIA 120 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Human Albumin 2%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2016-11-02",
      "completion_date": "2018-09-14",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 14,
      "location_summary": "Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722304"
    },
    {
      "nct_id": "NCT07555483",
      "title": "A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alpha 1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 15%",
          "type": "DRUG"
        },
        {
          "name": "Liquid Alpha1-PI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angelas",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07555483"
    },
    {
      "nct_id": "NCT01669421",
      "title": "Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 Antitrypsin (human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Campos, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669421"
    },
    {
      "nct_id": "NCT01983241",
      "title": "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Emphysema in Alpha-1 PI Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 MP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% Sodium Chloride for Injection, USP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 345,
      "start_date": "2013-11",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01983241"
    },
    {
      "nct_id": "NCT01213043",
      "title": "Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Emphysema",
        "Alpha 1-antitrypsin Deficiency (AATD)"
      ],
      "interventions": [
        {
          "name": "Prolastin-C, 60 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prolastin-C, 120 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-11",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-05-20",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01213043"
    },
    {
      "nct_id": "NCT04675086",
      "title": "Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19",
        "Pneumonia, Viral"
      ],
      "interventions": [
        {
          "name": "alpha1-proteinase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Antiviral Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blessing Corporate Services, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-01",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 1,
      "location_summary": "Hannibal, Missouri",
      "locations": [
        {
          "city": "Hannibal",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04675086"
    },
    {
      "nct_id": "NCT04547140",
      "title": "Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Liquid Alpha1-Proteinase Inhibitor (Human)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard Medical Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2021-01-29",
      "completion_date": "2022-01-28",
      "has_results": true,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-09-24T15:30:19.929Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Hannibal",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04547140"
    }
  ]
}